On 5/1/24, Catalyst Biosciences Inc (NASDAQ: CBIO) stock suffered a major decline of -11.2%, closing at $13.86. Moreover, this decline was accompanied by unusually high trading volume at 168% of normal. The stock has declined -13.0% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
CBIO is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment